Protagenic Therapeutics (PTIX) and Phytanix Bio said Monday that they have agreed to combine in an all-stock deal.
Shares almost quadrupled as intraday trading volume catapulted to over 80 million from a daily average of about 460,000.
BrainStorm Cell Therapeutics (BCLI) said it has received clearance from the US Food and Drug Administration to launch a phase 3b trial of NurOwn to treat amyotrophic lateral sclerosis.
Shares jumped 18%, with intraday trading volume at over 54 million versus a daily average of roughly 178,000.
Roth Capital raised its price target on Sable Offshore (SOC) to $38 from $26 while maintaining its buy rating.
Shares rose 20% as trading volume surged to more than 5.8 million from a daily average of about 1.6 million.
Price: 11.85, Change: +8.82, Percent Change: +291.22